AOD-9604

Overview

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic modified peptide fragment corresponding to the C-terminal region of human growth hormone (hGH), specifically residues 176-191, with an additional N-terminal tyrosine residue. It was developed by Professor Frank Ng and colleagues at Monash University in Melbourne, Australia, in collaboration with Metabolic Pharmaceuticals Limited, based on the observation that the lipolytic (fat-reducing) activity of growth hormone resides in a discrete region of the molecule distinct from the domains responsible for growth-promoting and diabetogenic effects.

The rationale behind AOD-9604 was to isolate the fat-metabolizing properties of growth hormone while eliminating the undesirable effects associated with full-length hGH administration, including insulin resistance, fluid retention, and potential proliferative risks. By using only the 176-191 fragment, the peptide retains the ability to stimulate lipolysis and inhibit lipogenesis without affecting blood glucose levels, IGF-1 concentrations, or other growth hormone-dependent anabolic pathways.

In 2007, the U.S. FDA granted AOD-9604 Generally Recognized as Safe (GRAS) status as a food supplement ingredient, a designation based on its favorable toxicology profile. The peptide has also attracted research interest for potential chondroprotective (cartilage-protective) properties, leading to investigation in osteoarthritis and musculoskeletal repair applications.

Mechanism of Action

AOD-9604 replicates the lipolytic mechanism of the C-terminal domain of growth hormone through a pathway that is distinct from and independent of the classical GH receptor/JAK2/STAT5 signaling cascade used by full-length hGH.

Beta-3 Adrenergic Receptor Pathway

Research by Ng et al. demonstrated that the hGH 176-191 fragment stimulates lipolysis in adipocytes through a mechanism involving the beta-3 adrenergic receptor (beta-3 AR) signaling pathway. The peptide enhances the activity of hormone-sensitive lipase (HSL) by promoting its phosphorylation via cyclic AMP-dependent protein kinase A (PKA). This activation cascade triggers the hydrolysis of stored triglycerides into free fatty acids and glycerol, which are subsequently released into circulation for oxidation. Critically, this lipolytic effect occurs without activation of the GH receptor’s JAK2/STAT5 pathway, which means AOD-9604 does not stimulate IGF-1 production or exhibit the growth-promoting, insulin-antagonizing, or proliferative effects of full-length growth hormone.

Lipogenesis Inhibition

In addition to promoting fat breakdown, AOD-9604 inhibits de novo lipogenesis (new fat formation) in adipose tissue. The proposed mechanism involves downregulation of key lipogenic enzymes including fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) through modulation of the sterol regulatory element-binding protein 1c (SREBP-1c) transcriptional pathway. This dual action — simultaneously enhancing fat catabolism while suppressing fat anabolism — produces a net negative lipid balance in adipose tissue.

Chondroprotective Mechanisms

More recent research has identified chondroprotective properties of AOD-9604 that appear mechanistically distinct from its lipolytic effects. In vitro studies demonstrated that AOD-9604 stimulates proteoglycan and collagen synthesis in articular chondrocytes, potentially through activation of the transforming growth factor-beta (TGF-beta) signaling pathway. The peptide also appears to inhibit matrix metalloproteinase (MMP) expression, reducing enzymatic degradation of cartilage extracellular matrix components. These findings suggest AOD-9604 may promote cartilage repair while simultaneously protecting against further degradation.

Research Summary

AOD-9604 has been investigated in preclinical models, clinical trials for obesity, and more recently in musculoskeletal applications. The research trajectory reflects both the promise and challenges of developing peptide-based anti-obesity therapeutics.

Preclinical Obesity Studies

Ng et al. (2000), published in Obesity Research, demonstrated that chronic administration of the hGH 176-191 fragment to obese (ob/ob) mice produced significant reductions in body weight and adipose tissue mass without affecting food intake, lean body mass, or serum IGF-1 levels. The fragment was effective at doses approximately 50-fold lower than those required for the equivalent lipolytic effect with full-length hGH. Importantly, unlike full-length hGH, the fragment did not induce hyperglycemia or insulin resistance, confirming the functional separation of the lipolytic domain from the diabetogenic regions of the growth hormone molecule.

Clinical Obesity Trials

Heffernan et al. (2001), published in Endocrinology, provided additional preclinical data showing that AOD-9604 enhanced fat oxidation in both lean and obese animal models. Subsequent Phase IIb clinical trials conducted by Metabolic Pharmaceuticals in 300 obese patients demonstrated statistically significant weight loss with AOD-9604 oral administration over 12 weeks. However, the magnitude of weight loss (approximately 1.6 kg more than placebo) was considered modest by regulatory standards, and the clinical development program for obesity was discontinued in 2007 before Phase III trials commenced.

Cartilage Repair Research

Krishnan et al. (2014), in a study presented at the Osteoarthritis Research Society International (OARSI) conference, demonstrated that intra-articular injection of AOD-9604 in a rat model of surgically induced osteoarthritis produced significant improvements in cartilage morphology scores and reduced proteoglycan degradation compared to saline controls. The study reported enhanced type II collagen deposition and reduced MMP-13 expression in the treated joints.

Safety and Metabolic Neutrality

Stier et al. (2004), published in the Journal of Endocrinology, confirmed the metabolic safety profile of AOD-9604 in a comprehensive study showing that chronic administration did not alter circulating IGF-1, insulin, glucose, cortisol, or thyroid hormone levels in treated animals. This metabolic neutrality, combined with the absence of anti-hGH antibody formation, supported the safety profile that ultimately contributed to the FDA GRAS determination for the compound.

Dosing in Published Research

AOD-9604 is a synthetic fragment of human growth hormone. It is not approved as a medicine and has no labeled dose. Its developer, Metabolic Pharmaceuticals, ran a Phase 2 obesity program in which AOD-9604 was given orally; a 1 mg daily dose produced the most weight loss (an average of about 2.6 kg versus 0.8 kg with placebo over 12 weeks), and a later Phase 2b study compared oral doses of 0.25, 0.5 and 1 mg per day. Notably, higher doses did not produce more weight loss. The obesity program was ultimately discontinued. These figures describe what was administered in those specific trials.

Safety and Side Effects

AOD-9604 is a synthetic fragment of human growth hormone, corresponding to residues 176 to 191, that was developed as a potential anti-obesity agent. In the clinical trials conducted during its development it was generally reported as well tolerated, with an adverse-effect profile similar to placebo and, notably, without the changes in IGF-1, glucose metabolism, or growth that characterize full growth hormone. Those trials were, however, of limited size and duration, and long-term safety has not been established. The principal limitation of AOD-9604 is not a specific documented hazard but the absence of demonstrated efficacy and the lack of any approved use; material sold as a research chemical is also of uncertain identity and purity.

Current Research Status

AOD-9604 was investigated for obesity but did not demonstrate sufficient efficacy to gain approval as a weight-loss drug; it is not approved by the FDA or any major regulatory agency as a therapeutic. It has been the subject of regulatory review as a food or supplement ingredient in some jurisdictions, but it holds no approved drug indication. It should be regarded as an investigational compound whose efficacy was not established.

Frequently Asked Questions